Toxicity of antiretroviral therapy and implications for drug development (Q35194751)

7 August 2017

1 reference

title

Toxicity of antiretroviral therapy and implications for drug development (English)

1 reference

7 August 2017

anti-retroviral agent

0 references

toxicity

0 references

author name string

Andrew Carr

series ordinal

1

1 reference

7 August 2017

1 August 2003

1 reference

Nature Reviews Drug Discovery

7 August 2017

1 reference

7 August 2017

2

1 reference

7 August 2017

8

1 reference

7 August 2017

624-634

1 reference

https://scigraph.springernature.com/pub.10.1038/nrd1151

7 August 2017

0 references

cites work

Adverse effects of antiretroviral therapy

1 reference

Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway

31 March 2020

1 reference

Mitochondrial toxicity of antiviral drugs

31 March 2020

1 reference

Weight loss in HIV-infected patients

31 March 2020

1 reference

Long-term hydroxyurea in combination with didanosine and stavudine for the treatment of HIV-1 infection. Swiss HIV Cohort Study

31 March 2020

1 reference

A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome.

31 March 2020

1 reference

Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA panel.

31 March 2020

1 reference

Fatal portal hypertension, liver failure, and mitochondrial dysfunction after HIV-1 nucleoside analogue-induced hepatitis and lactic acidaemia.

31 March 2020

1 reference

Liver failure after long-term nucleoside antiretroviral therapy

31 March 2020

1 reference

Chronic hyperlactatemia in HIV-infected patients taking antiretroviral therapy

31 March 2020

1 reference

A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors

31 March 2020

1 reference

Visceral abdominal-fat accumulation associated with use of indinavir

31 March 2020

1 reference

"Buffalo hump" in men with HIV-1 infection.

31 March 2020

1 reference

Benign symmetric lipomatosis associated with protease inhibitors

31 March 2020

1 reference

HIV-associated lipodystrophy

31 March 2020

1 reference

Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study

31 March 2020

1 reference

Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patients.

31 March 2020

1 reference

Insulin resistance in HIV protease inhibitor-associated diabetes

31 March 2020

1 reference

Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy

31 March 2020

1 reference

Increased risk of lipoatrophy under stavudine in HIV-1-infected patients: results of a substudy from a comparative trial

31 March 2020

1 reference

Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial

31 March 2020

1 reference

Clinical assessment of HIV-associated lipodystrophy in an ambulatory population

31 March 2020

1 reference

Abnormalities of body fat distribution in HIV-infected persons treated with antiretroviral drugs: The Swiss HIV Cohort Study

31 March 2020

1 reference

Lipodystrophy-associated morphological, cholesterol and triglyceride abnormalities in a population-based HIV/AIDS treatment database

31 March 2020

1 reference

Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study

31 March 2020

1 reference

Antiretroviral treatment patterns and incident HIV-associated morphologic and lipid abnormalities in a population-based chort

31 March 2020

1 reference

An objective case definition of lipodystrophy in HIV-infected adults: a case-control study

31 March 2020

1 reference

Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance.

31 March 2020

1 reference

Inhibition of adipocyte differentiation by HIV protease inhibitors

31 March 2020

1 reference

The HIV protease inhibitor indinavir impairs sterol regulatory element-binding protein-1 intranuclear localization, inhibits preadipocyte differentiation, and induces insulin resistance

31 March 2020

1 reference

HIV protease inhibitors block human preadipocyte differentiation, but not via the PPARgamma/RXR heterodimer

31 March 2020

1 reference

Suppression of preadipocyte differentiation and promotion of adipocyte death by HIV protease inhibitors

31 March 2020

1 reference

Association between altered expression of adipogenic factor SREBP1 in lipoatrophic adipose tissue from HIV-1-infected patients and abnormal adipocyte differentiation and insulin resistance

31 March 2020

1 reference

Evidence of nucleoside analogue reverse transcriptase inhibitor--associated genetic and structural defects of mitochondria in adipose tissue of HIV-infected patients

31 March 2020

1 reference

Mitochondrial DNA decrease in subcutaneous adipose tissue of HIV-infected individuals with peripheral lipoatrophy

31 March 2020

1 reference

HIV protease inhibitor substitution in patients with lipodystrophy: a randomized, controlled, open-label, multicentre study

31 March 2020

1 reference

Failure to maintain long-term adherence to highly active antiretroviral therapy: the role of lipodystrophy

31 March 2020

1 reference

Self-reported symptoms and medication side effects influence adherence to highly active antiretroviral therapy in persons with HIV infection.

31 March 2020

1 reference

Adverse effects of medications and trade-offs between length of life and quality of life in human immunodeficiency virus infection

31 March 2020

1 reference

Cardiovascular disease risk factors in HIV patients--association with antiretroviral therapy. Results from the DAD study

31 March 2020

1 reference

Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects.

31 March 2020

1 reference

Metabolic effects of indinavir in healthy HIV-seronegative men

31 March 2020

1 reference

HIV protease inhibitors protect apolipoprotein B from degradation by the proteasome: a potential mechanism for protease inhibitor-induced hyperlipidemia

31 March 2020

1 reference

Antiretroviral therapy-associated hyperlipidaemia in HIV disease

31 March 2020

1 reference

A single-nucleotide polymorphism in the sterol-regulatory element-binding protein 1c gene is predictive of HIV-related hyperlipoproteinaemia

31 March 2020

1 reference

31 March 2020

1 reference

Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile

31 March 2020

1 reference

The mechanism of insulin resistance caused by HIV protease inhibitor therapy.

31 March 2020

1 reference

The HIV protease inhibitor indinavir decreases insulin- and contraction-stimulated glucose transport in skeletal muscle

31 March 2020

1 reference

Abdominal fat and insulin resistance in normal and overweight women: Direct measurements reveal a strong relationship in subjects at both low and high risk of NIDDM.

31 March 2020

1 reference

Altered myocellular and abdominal fat partitioning predict disturbance in insulin action in HIV protease inhibitor-related lipodystrophy

31 March 2020

1 reference

Premature atherosclerosis in HIV-infected individuals--focus on protease inhibitor therapy

31 March 2020

1 reference

Evaluation of cardiovascular risk factors in HIV-1 infected patients using carotid intima-media thickness measurement

31 March 2020

1 reference

Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection

31 March 2020

1 reference

Protease inhibitors and cardiovascular outcomes in patients with HIV-1

31 March 2020

1 reference

Coronary heart disease in HIV-infected individuals

31 March 2020

1 reference

Cutaneous disease and drug reactions in HIV infection

31 March 2020

1 reference

Immunohistological assessment of cutaneous drug hypersensitivity in patients with HIV infection

31 March 2020

1 reference

Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir

31 March 2020

1 reference

Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy

31 March 2020

1 reference

Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection

31 March 2020

1 reference

Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection

31 March 2020

1 reference

Hepatitis B or hepatitis C virus infection is a risk factor for severe hepatic cytolysis after initiation of a protease inhibitor-containing antiretroviral regimen in human immunodeficiency virus-infected patients. The APROCO Study Group

31 March 2020

1 reference

Risk factors for hepatotoxicity in HIV-1-infected patients receiving ritonavir and saquinavir with or without stavudine. Prometheus Study Group

31 March 2020

1 reference

Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy

31 March 2020

1 reference

Late onset hepatitis and prolonged deterioration in hepatic function associated with nevirapine therapy

31 March 2020

1 reference

Hepatitis C virus-associated hepatitis following treatment of HIV-infected patients with HIV protease inhibitors: an immune restoration disease?

31 March 2020

1 reference

Restoration of immunity to chronic hepatitis B infection in HIV-infected patient on protease inhibitor

31 March 2020

1 reference

Focal mycobacterial lymphadenitis following initiation of protease-inhibitor therapy in patients with advanced HIV-1 disease.

31 March 2020

1 reference

Reactivation of hepatitis B in a long-term anti-HBs-positive patient with AIDS following lamivudine withdrawal

31 March 2020

1 reference

Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients

31 March 2020

1 reference

Chronic active hepatitis B exacerbations in human immunodeficiency virus-infected patients following development of resistance to or withdrawal of lamivudine

31 March 2020

1 reference

Reactivation of hepatitis B virus replication accompanied by acute hepatitis in patients receiving highly active antiretroviral therapy

31 March 2020

1 reference

Evolution of lamivudine-resistant hepatitis B virus and HIV-1 in co-infected individuals: an analysis of the CAESAR study. CAESAR co-ordinating committee

31 March 2020

1 reference

Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America

31 March 2020

1 reference

Efavirenz-induced psychosis leading to involuntary detention

31 March 2020

1 reference

Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients

31 March 2020

1 reference

Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study

31 March 2020

1 reference

Adherence to highly active antiretroviral therapy predicts virologic outcome at an inner-city human immunodeficiency virus clinic

31 March 2020

1 reference

The Dynamic of Adherence to Highly Active Antiretroviral Therapy: Results From the French National APROCO Cohort

31 March 2020

1 reference

Improvement of the study, analysis, and reporting of adverse events associated with antiretroviral therapy

31 March 2020

1 reference

Completeness of safety reporting in randomized trials: an evaluation of 7 medical areas

31 March 2020

1 reference

Quality of life assessment comes of age in the era of highly active antiretroviral therapy.

31 March 2020

1 reference

Low body weight and type of protease inhibitor predict discontinuation and treatment-limiting adverse drug reactions among HIV-infected patients starting a protease inhibitor regimen: consistent results from a randomized trial and an observational c

31 March 2020

1 reference

Predictors of protease inhibitor-associated adverse events

31 March 2020

1 reference

A randomised, open-label comparison of three highly active antiretroviral therapy regimens including two nucleoside analogues and indinavir for previously untreated HIV-1 infection: the OzCombo1 study

31 March 2020

1 reference

The revised CONSORT statement for reporting randomized trials: explanation and elaboration

31 March 2020

1 reference

Uniform requirements for manuscripts submitted to biomedical journals

31 March 2020

1 reference

Therapeutic drug monitoring: an aid to optimising response to antiretroviral drugs?

31 March 2020

1 reference

31 March 2020

Identifiers

DOI

10.1038/NRD1151

1 reference

7 August 2017

1 reference

PubMed ID

12904812